DEMANT Demant A/S

Demant A/S: Managers' transactions

Demant A/S: Managers' transactions

Company announcement no 2020-092 July 2020

Transactions with Demant A/S shares by senior executives and closely related parties

Notification pursuant to article 19, sub-article 2a, of the Market Abuse Regulation:

1.Details of the person discharging managerial responsibilities/person closely associated
a)NameAnja Madsen
2.Reason for the notification
a)Position/statusMember of the Board of Directors
b)Initial notification/amendmentInitial notification
3)Details of the issuer, emission allowance market participant, auction platform, auctioneer

or auction monitor
a)NameDemant A/S
b)LEI213800RM6L9LN78BVA56
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial

instrument, type of instrument



 



Identication code
Shares



 



 



DK0060738599
b)Nature of the transactionPurchase
c)Price(s) and volume(s)Price  Volume

DKK 176.20  751 shares

DKK 176.00  100 shares
d)Aggregated information:

- Aggregated volume

- Price
 



851 shares

DKK 176.37
e)Date of the transaction29 June 2020
f)Place of the transactionNasdaq Copenhagen A/S

* * * * * * *

Further information:

Christian Lange, Investor Relations Officer

Trine Kromann-Mikkelsen, VP Corporate Communication and Relations

Phone

 

 

Attachment

EN
02/07/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Demant A/S

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
Rune Majlund Dahl
  • Rune Majlund Dahl

Demant (Buy, TP: DKK300.00) - Headwinds set to persist in Q1

We forecast Q1 organic sales growth of just 0.6% YOY, below the full-year guidance, owing to persistent headwinds in wholesale. However, with Managed Care headwinds set to annualise from Q2, better quarters should lie ahead. We expect an unchanged 2025 guidance of 3–7% organic sales growth and DKK4.5bn–4.9bn in EBIT, but we find the lower end most likely. We reiterate our BUY but have cut our target price to DKK300 (320).

ResearchPool Subscriptions

Get the most out of your insights

Get in touch